FAP-2286 is a synthetic peptide commercialized by Clovis Oncology, with a leading Phase II program in Gallbladder Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of FAP-2286’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for FAP-2286 is expected to reach an annual total of $25 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

FAP-2286 Overview

3B-201 is under development for the treatment of solid tumors including colorectal cancer, pancreatic ductal adenocarcinoma, adenoid cystic carcinoma, gallbladder cancer, head and neck cancer squamous cell carcinoma, neuroblastoma, soft tissue sarcoma. The drug candidate comprises of PurAffin ligands which are chemically stabilized peptide ligands (peptidomimetics) coupled to a therapeutic radioisotope via a linker and a chelator. The drug candidate is developed based on PurAffin technology. It acts by targeting Fibroblast Activation Protein Alpha (FAP). It is administered through intravenous route.

Clovis Oncology Overview

Clovis Oncology (Clovis) is a biopharmaceutical company that develops and commercializes anti-cancer agents in the US and internationally. The company’s lead product includes Rubraca, an oral small molecule inhibitor of poly ADP-ribose polymerase used for the treatment of adults with BRCA mutation-associated metastatic castrate-resistant prostate cancer. Its major pipeline products include Rucaparib, which is intended for the treatment of ovarian cancer, prostate cancer, gastric cancer, and solid tumors with mutations in homologous recombination repair genes. The company’s preclinical candidate, FAP-2286 is a peptide-targeted radionuclide therapy and imaging agent intended for the treatment of cancer. It operates in California, the US; Cambridge, the UK; and Milan, Italy; among others. Clovis is headquartered in Boulder, Colorado, the US.

The company reported revenues of (US Dollars) US$148.8 million for the fiscal year ended December 2021 (FY2021), a decrease of 9.6% over FY2020. The operating loss of the company was US$228.1 million in FY2021, compared to an operating loss of US$340.5 million in FY2020. The net loss of the company was US$264.5 million in FY2021, compared to a net loss of US$369.2 million in FY2020. The company reported revenues of US$30.7 million for the third quarter ended September 2022, a decrease of 4.6% over the previous quarter.

For a complete picture of FAP-2286’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.